RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024FARMINGTON HILLS, Mich., and PITTSBURGH, Sept.…
Louvain-La-Neuve, Belgium, September 27, 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading…
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced…
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology…
Todd Edwards Chief Commercial Officer, Arcutis BiotherapeuticsIndustry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice…
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSDROCKAWAY, N.J., Sept. 27, 2023 (GLOBE…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform…
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be…
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept.…
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine…